Illinois College Of Optometry

Perfluorohexyloctane Shows Promise for Dry Eye Disease in Pooled Phase 3 Analysis

8 months ago

• Pooled data from two Phase 3 trials (GOBI and MOJAVE) demonstrate that perfluorohexyloctane ophthalmic solution significantly improves signs and symptoms of dry eye disease (DED). • The analysis included patients with DED associated with Meibomian gland dysfunction (MGD), showing efficacy across various demographic and disease severity subgroups. • Perfluorohexyloctane led to greater reductions in total corneal fluorescein staining (tCFS) and eye dryness visual analog scale (VAS) scores compared to hypotonic saline control. • The most common adverse event was mild, transient blurred vision, suggesting perfluorohexyloctane is generally well-tolerated for treating DED.